GANX Gain Therapeutics
- 2.970
- +0.040+1.37%
Gain Therapeutics News
Buy Rating Affirmed for Gain Therapeutics on Promising GT-02287 Clinical Progress
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Acrivon Therapeutics, Inc. (ACRV) and Gain Therapeutics (GANX)
Gain Therapeutics Shares Rise 8% After Positive Results From Early Trial of Parkinson's Disease Therapy
By Chris Wack Gain Therapeutics shares rose after the company said it saw positive results from an early study of its potential Parkinson's Disease therapy. Shares were up 8% to $3.65 in early tradi
Express News | Gain Therapeutics Announces Positive Results From the Single Ascending Dose (Sad) Part of the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Gba1 Parkinson’s Disease
Express News | Oppenheimer Maintains Outperform on Gain Therapeutics, Maintains $9 Price Target
Oppenheimer Remains a Buy on Gain Therapeutics (GANX)
Here's Why Gain Therapeutics (GANX) Could Be Great Choice for a Bottom Fisher
Insiders Are Piling Into These 10 Healthcare Stocks in 2024
Gain Therapeutics Welcomes New CFO Gene Mack
Express News | Gain Therapeutics Appoints Gene Mack As CFO
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Appoints Gene Mack as Chief Financial Officer >GANX
Gain Therapeutics Bolsters Management Team With the Appointment of Gene Mack as Chief Financial Officer
Gain Therapeutics, Inc. (Nasdaq: GANX) today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)
NVCR, SBNY and VITL Are Among After Hour Movers
Gain Therapeutics(GANX.US) Director Buys US$115.77K in Common Stock
$Gain Therapeutics(GANX.US)$ Director Riley Jeffrey Scott purchased 30,000 shares of Common Stock on Mar 28, 2024 at an average price of $3.859 for a total value of $115.77K.Source: Announcement What
Gain Therapeutics Gets New Chief Medical Officer
Express News | HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson's Drug Candidate GT-02287
Gain Therapeutics Price Target Maintained With a $6.00/Share by Chardan Capital
Gain Therapeutics Price Target Maintained With a $6.00/Share by Chardan Capital
Analysis
Price Target
No Data
